Research use only, not for human consumption. Email [email protected]
← Research status explorer
Neuro / Cognitive

Selank

Current research status Human Research
Limited/regional clinical research
Preclinical
Human Research

What is it?

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed as an analogue of tuftsin, a short endogenous immunomodulatory peptide, with a Pro-Gly-Pro sequence added to the tuftsin tetrapeptide. It was developed in Russia, and most of the published work on it comes from Russian research groups. It has been studied in animals and in small regional clinical studies for anxiolytic, cognitive and immune-related effects. Much of the research is in regional journals, and independent replication is limited.

Research overview

Selank is a synthetic peptide analogue of tuftsin, also developed and studied mainly in Russia for anxiolytic and nootropic effects, and registered there as a nasal-spray medication. As with Semax, its human evidence comes largely from regional research rather than an FDA-recognized development program.

Mechanism of action

The mechanisms proposed for Selank are still hypotheses. One line of work reports that Selank inhibits enzymes that degrade enkephalins (endogenous opioid peptides) in blood plasma in vitro, which has been suggested as a basis for its anxiolytic activity [PMID 11550013]. This is an in vitro finding, not proof of mechanism in people.

A second line of work concerns the GABA system. In rat frontal cortex, a gene-expression panel reported changes in many neurotransmission-related genes after Selank, with a positive correlation to the changes seen after GABA, and the authors proposed allosteric modulation of the GABAergic system [PMID 26924987]. A radioligand binding study reported that Selank acted as a positive allosteric modulator of [3H]GABA binding in brain membranes [PMID 30255741]. However, a cell-culture study in IMR-32 neuroblastoma cells found no change in GABA-system gene mRNA levels with Selank alone, and only partial support for an interaction with GABA at GABA-A receptors [PMID 28293190]. The GABA hypothesis is therefore supported by some findings and not others.

A third line concerns immune signalling, consistent with Selank's tuftsin origin. In mouse spleen, a gene-expression panel reported altered expression of 34 inflammation-related genes after a single injection of Selank or its fragments [PMID 21609736]. In small human samples, changes in the Th1/Th2 cytokine balance were reported in patients receiving Selank, and in vitro cell experiments reported effects on IL-6 gene expression [PMID 18577961]. Whether these gene-expression and cytokine changes explain any behavioural or clinical effect has not been established.

Adult human evidence

The human literature on Selank is small and comes almost entirely from Russian clinical groups publishing in a regional journal (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova). The abstracts reviewed describe patient studies in anxiety-spectrum disorders. Three further Russian clinical reports of Selank in anxiety-spectrum disorders are not summarised here: their PubMed records carry an adolescent age tag and their abstracts give no age range, so they cannot be confirmed as adult-only evidence.

An immunological study reported that Th1/Th2 cytokine balance changed in the serum of patients with generalised anxiety disorder and neurasthenia who received Selank for 14 days, and that Selank altered IL-6 gene expression in cultured blood cells from patients with depression [PMID 18577961]. A placebo-controlled resting-state fMRI study in 52 healthy participants compared Selank, Semax and placebo and reported differences in functional connectivity between the right amygdala and a region of the right temporal cortex [PMID 32342318]. That study measured brain connectivity, not anxiety outcomes.

The human data that can be confirmed as adult are therefore limited to an immunological report and a brain-imaging study, which measure biomarkers and connectivity, not clinical outcomes. No placebo-controlled clinical efficacy trial in confirmed adults was identified, all of the work comes from Russian groups publishing in regional journals, and no independent replication was found.

Preclinical evidence

In rats, a gene-expression panel of 84 neurotransmission-related genes in the frontal cortex reported significant changes in 45 genes one hour after a single administration of Selank and in 22 genes after three hours, with changes correlating with those caused by GABA [PMID 26924987]. In contrast, Selank alone did not change the expression of GABA-system genes in cultured IMR-32 neuroblastoma cells, although combinations with GABA or olanzapine altered the expression profile [PMID 28293190]. A radioligand binding study in brain membranes reported that Selank modulated [3H]GABA binding as a positive allosteric modulator and could block the modulatory activity of diazepam and olanzapine in that assay [PMID 30255741].

In vitro work using plasma reported that Selank dose-dependently inhibited enzymatic breakdown of enkephalins and was more potent than the peptidase inhibitors bacitracin and puromycin in the same assay [PMID 11550013]. This preparation also included measurements in patients with anxiety disorders; the inhibition experiments themselves were done in vitro.

In mice, a gene-expression study reported significant changes in 34 inflammation-related genes in the spleen 6 and 24 hours after a single injection of Selank, with similar changes for fragments such as Gly-Pro [PMID 21609736]. These are transcript-level observations in a single tissue, and they have not been linked to a specific functional outcome.

Evidence limitations

  • Human evidence is limited to a few small, regional studies by overlapping Russian research groups; independent replication and large placebo-controlled trials were not identified.
  • The abstracts do not describe blinding or randomisation methods, and comparators were often established anxiolytics (medazepam, phenazepam) rather than placebo, so effects relative to placebo cannot be judged.
  • Participant ages are not stated in the abstracts reviewed; PubMed indexing suggests mostly adult participants, but this should be confirmed from the full papers.
  • The mechanism is unresolved: the enkephalinase, GABA-modulation and immune-gene-expression findings come from different models, and one cell-based study found no direct effect on GABA-system gene expression.
  • Much of the preclinical work consists of gene-expression and binding measurements in rodents and cultured cells, which do not show that the same changes occur or matter in humans.
  • Long-term safety, pharmacokinetics in humans and regulatory approval outside Russia were not established in the sources reviewed.

Research and regulatory status

Selank is described in the Russian-language literature as a locally developed anxiolytic, and the site's research summary notes it as human-researched mainly in regional studies. Its registration or regulatory status as a medicine in any country was not independently verified in this review. A search of ClinicalTrials.gov on 2026-11-20 found no Selank studies (the matches returned were unrelated records), and a 2020 analytical paper reported that Selank and Semax had, to the authors' knowledge, not completed any clinical trials and were available online outside regulated channels [PMID 31667971].

Key studies

Adult human study

Immunomodulatory effects of selank in patients with anxiety-asthenic disorders

Uchakina ON, Uchakin PN, Miasoedov NF, et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2008

Design
In vitro cell culture experiments plus an in vivo cytokine measurement in patients receiving Selank for 14 days
Participants / model
Peripheral blood cells from patients with depression and healthy controls (in vitro); serum from patients with generalised anxiety disorder and neurasthenia (in vivo)
Sample size
not stated in the abstract
Principal findings
Selank was reported to suppress IL-6 gene expression in blood cells from patients with depression but not from healthy controls in vitro, and changes in the Th1/Th2 cytokine balance were reported in patients' serum after 14 days of Selank.
Limitations
Sample sizes and controls are not stated in the abstract. Immune markers were measured rather than clinical outcomes, and the study is from a regional journal.

PubMed 18577961

Adult human study

Functional Connectomic Approach to Studying Selank and Semax Effects

Panikratova YR, Lebedeva IS, Sokolov OY, et al. · Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2020

Design
Placebo-controlled resting-state fMRI study (scans before and 5 and 20 minutes after Selank, Semax or placebo)
Participants / model
Healthy participants; regions of interest were the amygdala and dorsolateral prefrontal cortex
Sample size
52 healthy participants
Principal findings
Between-group and between-condition differences were reported in functional connectivity between the right amygdala and a region of the right temporal cortex (fusiform, inferior and middle temporal and parahippocampal gyri).
Limitations
Acute, short-term effects in healthy volunteers; the abstract reports no anxiety or cognitive outcomes, and group sizes per arm are small.

PubMed 32342318 DOI 10.1134/S001249662001007X

Preclinical (animal / cell)

Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission

Volkova A, Shadrina M, Kolomin T, et al. · Frontiers in pharmacology · 2016

Design
Rat gene-expression study (real-time PCR panel of 84 neurotransmission genes)
Participants / model
Frontal cortex of rats, 1 and 3 hours after administration of Selank or GABA
Sample size
not stated in the abstract
Principal findings
Significant expression changes were reported in 45 genes at 1 hour and 22 genes at 3 hours, with a positive correlation between the changes caused by Selank and by GABA. The authors proposed allosteric modulation of the GABAergic system as one possible mechanism.
Limitations
Transcript-level changes in a single brain region; no behavioural or protein-level outcomes in the abstract.

PubMed 26924987 DOI 10.3389/fphar.2016.00031

Preclinical (animal / cell)

GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells

Filatova E, Kasian A, Kolomin T, et al. · Frontiers in pharmacology · 2017

Design
In vitro cell culture study (qPCR panel of 84 genes)
Participants / model
Human IMR-32 neuroblastoma cells treated with Selank, GABA, olanzapine and combinations
Sample size
not stated in the abstract
Principal findings
No changes in the mRNA levels of the genes studied were found with Selank alone. Combined treatment with GABA suppressed GABA-induced expression changes, and combination with olanzapine altered the expression of more genes than olanzapine alone.
Limitations
A tumour-derived cell line with no behavioural readout; the result did not show a direct effect of Selank alone, which partly conflicts with the in vivo gene-expression findings.

PubMed 28293190 DOI 10.3389/fphar.2017.00089

Preclinical (animal / cell)

Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity

Vyunova TV, Andreeva L, Shevchenko K, et al. · Protein and peptide letters · 2018

Design
In vitro radioligand receptor-binding study (despite the title, an experimental paper rather than a literature review)
Participants / model
Isolated brain cell plasma membranes, [3H]GABA binding with Selank, diazepam and olanzapine
Sample size
not stated in the abstract
Principal findings
Selank was reported to affect [3H]GABA binding as a positive allosteric modulator, and to block the modulatory activity of diazepam and olanzapine in the assay. The authors proposed subtype-selective allosteric modulation of GABA receptors as one possible anti-anxiety mechanism.
Limitations
Membrane binding assay only; binding sites were not identified and there is no behavioural or in vivo confirmation in this paper.

PubMed 30255741 DOI 10.2174/0929866525666180925144642

Preclinical (animal / cell)

The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity

Zozulya AA, Kost NV, Yu Sokolov O, et al. · Bulletin of experimental biology and medicine · 2001

Design
In vitro enzyme inhibition assay using plasma, with measurements in patients with anxiety and phobic disorders
Participants / model
Blood plasma enkephalin hydrolysis; patients with anxiety disorders (DSM-4) for enkephalin half-life and enkephalinase activity
Sample size
not stated in the abstract
Principal findings
Selank was reported to inhibit enkephalin hydrolysis in plasma in a dose-dependent way and more potently than bacitracin and puromycin. Patients with generalised anxiety, but not panic disorder or agoraphobia, were reported to show shortened enkephalin half-life and reduced enkephalinase activity.
Limitations
Old regional-journal study; in vitro enzyme inhibition does not show that the mechanism operates in vivo, and the link to anxiolytic effects is a hypothesis.

PubMed 11550013 DOI 10.1023/a:1017979514274

Preclinical (animal / cell)

Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank

Kolomin T, Shadrina M, Andreeva L, et al. · Regulatory peptides · 2011

Design
Mouse gene-expression study (real-time PCR panel of 84 inflammation-related genes)
Participants / model
Mouse spleen 6 and 24 hours after a single intraperitoneal injection of Selank or two fragments
Sample size
not stated in the abstract
Principal findings
Significant expression changes in 34 inflammation-related genes were reported, including changes in Bcl6 and its target and corepressor genes after Selank and each fragment.
Limitations
Transcript-level changes in one tissue after a single administration; no functional immune outcome is reported in the abstract.

PubMed 21609736 DOI 10.1016/j.regpep.2011.05.001

Review

The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind

Vanhee C, Francotte A, Janvier S, et al. · Drug testing and analysis · 2020

Design
Analytical (LC-MS/MS) study of seized preparations with an online availability search; not a clinical review
Participants / model
Two suspicious preparations seized in 2017 and 2018 that were found to contain Selank and Semax
Sample size
2 seized preparations
Principal findings
The preparations contained Selank and Semax, which the authors noted, to their knowledge, had not completed any clinical trials. An online search found such peptides freely available as lyophilised powder or in nasal sprays, and the authors developed an LC-MS/MS method for detecting them.
Limitations
Addresses regulation and analytical detection, not efficacy or safety. The statement about clinical trials reflects the authors' knowledge at the time and does not account for Russian regional studies.

PubMed 31667971 DOI 10.1002/dta.2717

Last reviewed: 20 November 2026